AstraZeneca introduced a new experimental drug that shrank tumors in 51 percent of cancer patients. The company has dubbed it as the "new great white hope" in its battle not only against cancer but also against Pfizer's planned takeover.
AstraZeneca introduced a new experimental drug that shrank tumors in 51 percent of cancer patients. The company has dubbed it as the "new great white hope" in its battle not only against cancer but also against Pfizer's planned takeover.